Vaxcyte
PCVX
285 hedge funds and large institutions have $5.09B invested in Vaxcyte in 2025 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 100 increasing their positions, 103 reducing their positions, and 44 closing their positions.
389% more call options, than puts
Call options by funds: $20.9M | Put options by funds: $4.27M
6% more capital invested
Capital invested by funds: $4.8B → $5.09B (+$292M)
3% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 103
9% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 44
3% less funds holding
Funds holding: 294 → 285 (-9)
5.53% less ownership
Funds ownership: 114.35% → 108.82% (-5.5%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$76.7M |
| 2 |
D.E. Shaw & Co
New York
|
+$39.8M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$28.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.1M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$130M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$52.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$49.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$29.3M |
| 5 |
BlackRock
New York
|
-$22.7M |
PCVX Hedge Fund Activity: Q3 2025 in Review
285 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q3 2025, worth a combined $5.09B — up 6.1% from $4.8B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of PCVX and 40 opened new positions — a net loss of 4 holders — while 103 trimmed existing stakes and 100 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $76.7M. The largest seller was Capital Research Global Investors, cutting an estimated $130M.
- 285 institutional investors held Vaxcyte (PCVX) as of Q3 2025, down from 294 in Q2 2025.
- Funds reported $5.09B of Vaxcyte stock for Q3 2025, up 6.1% quarter-over-quarter.
- 40 funds opened new Vaxcyte positions in Q3 2025 and 44 closed out, a net change of -4 holders.
- The largest Vaxcyte buyer in Q3 2025 was T. Rowe Price Investment Management, an estimated $76.7M added.
- The largest Vaxcyte seller in Q3 2025 was Capital Research Global Investors, an estimated $130M sold.
Based on aggregated 13F filings for Q3 2025.